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Abstract
Background: ErbB3-binding protein 1 (Ebp1) is a member of the PA2G4 family of proliferation-
regulated proteins that is expressed in multiple malignant and non-malignant cells. ErbB3 and other
members of the EGFR family have been implicated in cancer progression, it however remains
unknown whether Ebp1 participate in prostate cancer progression in vivo. Therefore, the present
study examines Ebp1 expression in cancerous and non-cancerous prostates tissues. Ebp1
expression was also correlated to known Ebp1 regulated proteins (Androgen receptor (AR), Cyclin
D1 & ErbB3) and the proliferation marker Ki67. Furthermore we evaluated whether Ebp1
expression correlated with biochemical recurrence (BCR) following radical prostatectomy.
Methods:  The expression of Ebp1, AR, Cyclin D1, ErbB3 and Ki67 were evaluated by
immunohistochemistry using three separate tissue micro-arrays containing normal prostate tissues,
non-cancerous tissue adjacent to the primary tumor, hormone-sensitive and hormone-refractory
cancerous tissues. Multivariate COX regression analysis was performed with four clinical
parameters in order to correlate Ebp1 expression with PCa progression.
Results: The expression of Ebp1 significantly increased with the progression from normal to
hormone sensitive and to hormone refractory PCa. Furthermore, we observed strong correlation
between Ebp1 expression and the nuclear expression of AR, Cyclin D1 and ErbB3 in both normal
adjacent and cancer tissues. The expression of AR, Cyclin D1 and ErbB3 in normal adjacent tissues
correlated with PSA relapse, whereas Ebp1 on its own did not significantly predict PSA relapse.
Finally, in a multivariate analysis with a base clinical model (Gleason, Pre-op PSA, surgical margins
and P-stage) we identified the multi-marker combination of Ebp1+/Cyclin D1- as an independent
predictor of PSA relapse with a hazard ratio of 4.79.
Conclusion: Although not related to disease recurrence, this is the first in vivo study to report
that Ebp1 expression correlates with PCa progression.
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Background
Prostate cancer is a major public health concern in North
American and European countries. Through improve-
ments in diagnostic methods and increased awareness,
greater than 90% of patients are now being diagnosed
with localized or regionally advanced prostate cancer [1].
Nonetheless, between 15% and 35% of patients will
develop prostate specific antigen (PSA) relapse within 10
years following surgery [2,3]. As the course of the disease
is quite variable, progress needs to be made in the estab-
lishment of clinical tests that could help identify patients
at risk of recurrence and progression. The molecular char-
acterization of tumor cells through immunohistochemi-
cal analysis offers the opportunity to better stratify
patients early in the disease process.
We and other groups have recently demonstrated an asso-
ciation between the nuclear localization of ErbB3, an epi-
dermal growth factor receptor, and prostate cancer
progression [4-6]. A protein directly interacting with
ErbB3 and known to transduce growth regulatory signals
is ErbB3-binding protein 1 (Ebp1). Cytoplasmic Ebp1
associates with the cytoplasmic domain of ErbB3 and fol-
lowing heregulin activation of ErbB3, Ebp1 dissociates
from the receptor and translocates to the nucleus [7].
Ebp1 is a member of the PA2G4 family of proliferation-
regulated proteins that is ubiquitously expressed in the
cytoplasm and nucleus of multiple malignant and non-
malignant cells [7,8]. Ebp1 activity may be involved in
tumorigenesis through its roles in cellular proliferation
and regulation of gene expression. In breast and prostate
cancer, as well as in human fibroblasts, the ectopic expres-
sion of Ebp1 can limit cellular proliferation and promote
differentiation [9,10]. Ebp1 can also repress the transcrip-
tion of androgen receptor (AR) and Cyclin D1, through
physically binding to the AR or by interacting with the his-
tone deacetylase HDAC2 and the tumor suppressor Retin-
oblastoma (Rb) [10-13].
There are currently few studies describing the expression
of Ebp1 in tumor tissues and its clinico-pathological rele-
vance. Ebp1 is expressed in prostate and breast cancer pri-
mary culture [8]. A recent publication also showed an
overexpression of Ebp1 in colorectal cancers compared to
normal areas adjacent to the cancer [14]. To our knowl-
edge the present study is the first to characterize the
expression of Ebp1 in prostate cancer patients. Consider-
ing the important role of the AR in prostate cancer pro-
gression and possible regulation of AR expression by
Ebp1, we deemed it necessary to evaluate the co-expres-
sion of Ebp1 with nuclear AR. Furthermore, since Ebp1 is
involved in cellular proliferation, we also evaluated the
co-expression of Ebp1 with two proliferation markers,
Cyclin D1 and Ki67. Finally, the interaction between
Ebp1 and ErbB3 was also studied. This report offers direct
evidence that the high expression of Ebp1 correlates with
the presence of prostate cancer as well as a double marker
combination that includes Ebp1 that can help predict PSA
relapse following radical prostatectomy.
Methods
Patient cohort
Three different tissue micro-arrays (TMAs) were used in
this study. The first TMA contained 39 normal prostate
specimens obtained from patients autopsied and will be
referred to as the normal-TMA (N-TMA). A second TMA
contained tumor tissue obtained by trans-urethral resec-
tions of the prostate (TURP) from 36 hormone refractory
patients collected subsequent to hormone therapy failure.
This second TMA will be referred to as the hormone-
refractory TMA (HR-TMA). Finally, 62 patients who had
undergone radical prostatectomy were selected for the cre-
ation of a third TMA based on the following inclusion cri-
teria: no preoperative hormone therapy, follow-up of a
minimum of 5 years or until death and received no radio-
therapy or hormone therapy prior to biochemical failure
[15]. This third TMA will be referred to as the radical pros-
tatectomy TMA (RP-TMA). This sub-cohort of 62 hor-
mone sensitive patients was used to evaluate the
prognostic value of the molecular markers used in this
study. The failure interval was defined as the time between
radical prostatectomy and the first PSA reading above 0.2
to 0.4 ng/ml [14]. There was no age difference between
the group of patients that develop PSA relapse and the
group that did not. Clinical and pathological characteris-
tics of the patients selected for the RP-TMA are presented
in Table 1. The final pathological staging and grading was
based on pathology reports from the CHUM Hôpital
Notre-Dame. Ethics approval for this study was obtained
from the local IRB committee and all patients signed con-
sent forms.
Tissue micro-array
We have previously described in detail TMAs obtained
from normal prostate tissues and hormone refractory
TURP specimens [16]. The third RP-TMA was built in
duplicate and contained a total of 2 normal adjacent and
4 tumor 1.0 mm cores per patients for all 62 patients
[15,16]. Two pathologists evaluated H&E staining of each
TMA and confirmed the proper histological status each
core.
Characterization of normal adjacent tissue
Each core classified as normal adjacent was reviewed inde-
pendently by two pathologists in a blinded manner. None
of the normal adjacent cores contained histopathological
evidence of neoplasia. To ensure that the normal adjacent
cores were not cancerous and did not contain observable
pre-neoplastic lesions, we evaluated the integrity and con-Cancer Cell International 2008, 8:18 http://www.cancerci.com/content/8/1/18
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tinuity of the basal membrane. By immunohistochemistry
using an antibody that recognizes cytokeratins 1, 5, 10
and 14, we were able to distinguish between adenocarci-
noma and non-adenocarcinoma of the prostate (Figure 1)
[17]. From the 62 patients represented on the RP-TMA, 9
patients were removed because their corresponding nor-
mal adjacent cores did not satisfy our inclusion criteria,
two of which developed biochemical recurrence. Statisti-
cal analyses were thus based on 53 patients for marker
expression in normal adjacent tissues and 62 patients for
marker expression in tumor tissues.
Immunohistochemistry
Immunohistochemical staining of the prostate cancer
TMAs was done as previously described [4,15]. Briefly,
TMAs were deparaffinized in toluene and rehydrated in a
gradient of ethanol. Endogenous peroxidase activity was
quenched during a 30 min incubation with 0.3% H2O2/
methanol. A 15 min incubation in boiling citrate solution
(10 mM, pH 6.0) followed by a 15 min incubation at
room temperature was used for antigen retrieval. Subse-
quently, a protein blocking serum-free reagent (Dako
Cytomation Inc., Mississauga, Ontario, Canada) was
applied for 15 min. The 60 min primary antibody incuba-
tion was completed in a humidified chamber with the fol-
lowing antibodies: Androgen receptor (Ab1, Labvision
Neomarkers, CA, USA), Cyclin D1 (Ab4, Labvision Neo-
markers), Cytokeratin EβE12 recognizing cytokeratins 1,
5, 10 and 14 (Chemicon, CA, USA), Ebp1 (07-397,
Upstate, Lake Placid, NY, USA), ErbB3 (Sc-285, Santa
Cruz biotechnology, CA, USA) and Ki67 (SP-6, LabVision
NeoMarkers). The optimal dilution for each antibody was
determined by serial dilutions. After stringent washes in
PBS, the TMAs were incubated for 20 min with a second-
ary biotinylated antibody followed by 20 min incubation
with a streptavidin-peroxidase complex (both from Dako
Cytomation). Positive signal was developed with diami-
nobenzidine (DAB) (Dako Cytomation) and the nuclei
were counterstained with haematoxylin.
Interpretation of immunohistochemistry results
TMAs were evaluated through a 20× objective using a
bright field microscope. For the Ebp1 expression analysis,
each core was given a score based on the cytoplasmic
staining intensity from 0 to 3 (Figure 2a). For AR, Cyclin
D1 and ErbB3, each core was given a score based on the
percentage of cells showing positively stained nuclei (Fig-
ure 3). Two independent observers analyzed each TMA in
a blinded manner. Inter-observer scoring correlation was
0.75 to 0.9. The average of both observations was reported
for statistical analysis. The quantification of Ki67 expres-
sion was completed with an image analysis software, as
previously described by our group, due inherent staining
properties, which, unlike the AR, Cyclin D1 and ErbB3,
Ki67 strictly localizes to the nucleus [18]. Briefly, a digital
image of each core was analyzed with the Image Pro Plus
v.5.0 software (MediaCybernetics) and a score represent-
ing the number of Ki67 positive (+) nuclei was obtained.
The average number of both tumor cores, and the value
for the normal core, was used for statistical analysis. Since
ROC analyses did not give statistically significant results,
data for all five markers were categorized according to the
median staining expression. This median was used as a
cut-offs for each marker in order to create multi-marker
combinations.
Statistics
Statistical analysis was performed using with SPSS soft-
ware 11.0 (SPSS Inc. Chicago, Illinois, USA). The median
score of both normal adjacent tissues and tumor tissues
were used as cutoff values, thus giving two independent
scores for each marker: i.e. a normal adjacent value and a
tumor value. Since not all marker expression had normal
Table 1: Clinical and pathological characteristics of patients in 
the RP-TMA.
Number of patients selected 62
Age median (min-max) 62 (49 – 70)
Pathological Stage
Stage 2 34 (54.8%)
Stage 3 29(46.8%)
Invasion
Extracapsular 19(30.6%)
Lymph node 9(14.5%)
Perineural 9(14.5%)
Positive surgical margins 32(51.6%)
Prostatitis 1 (1.6%)
Gleason score
Gleason 4 8 (12.9%)
Gleason 5 14 (22.6%)
Gleason 6 13 (21.0%)
Gleason 7 17(27.4%)
Gleason 8–9 10(16.1%)
Pre-operative PSA
<10 ng 35 (56.5%)
> 10 ng 25 (40.3%)
not available 2 (3,2%)
PSA relapse 35 (56.5%)
Hormone refractory disease 5(8.1%)
Overall survival 54(87.1%)
Clinico-pathological parameters of the 62 patients selected for the 
construction of the RP-TMA.Cancer Cell International 2008, 8:18 http://www.cancerci.com/content/8/1/18
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distribution and equal variance, the non-parametric
Mann-Whitney U test was used to show significant differ-
ences between the normal, normal adjacent, PIN, tumor
and HR groups. Correlations between markers were done
using the non-parametric Spearman's rank correlation
coefficient. The median marker expression was used to
categorize data in dichotomized variables (positive or
negative). The median value in normal adjacent tissues
was used to categorize normal adjacent expression and the
median value in tumor tissues was used to categorize
tumor expression. This approach has been demonstrated
to be statistically reliable [19,20]. Marker combinations
were determined using these dichotomized values. For
example, the combined value "Ebp1+/Cyclin D1- in nor-
mal adjacent" was created based on a positive Ebp1
expression (above normal adjacent median) and negative
Cyclin D1 expression (below normal adjacent median).
The Wald test was used for Cox proportional hazards
regression analysis in univariate and multivariate models.
The data was tested and met the assumptions for using
Cox test. Gleason score (< 7, 7, > 7), pre-operative PSA lev-
els (as a continuous variable), surgical margin status and
pathological stage were included in the multivariate anal-
yses as clinical parameters known to correlate with PSA
relapse.
Results
Ebp1 expression correlates with the presence of prostate 
cancer
The expression of Ebp1 was analyzed by immunohisto-
chemistry in a total 138 prostates from patients with or
without prostate cancer. In the 138 patients analyzed, we
did not observe any nuclear localization of Ebp1. The
cytoplasmic expression of Ebp1 was therefore studied. We
observed a progressive increase in the cytoplasmic stain-
ing intensity of Ebp1 from normal tissue of patients with
no prostate cancer to the more malignant hormone refrac-
tory tumors (Figure 2b). We also observed an increase in
Ebp1 expression in tumor tissue compared to normal
adjacent tissue (P < 0.001, Mann-U). Interestingly, there
was a significant difference in the expression of Ebp1
between normal (from patients without prostate cancer)
and normal adjacent tissues (from patients with prostate
cancer) (P < 0.001, Mann-U). There was also a significant
increase in the expression of Ebp1 in hormone refractory
tumors compared to hormone sensitive tumors (P  <
0.001, Mann-U). We further evaluated whether Ebp1
expression correlated with the Gleason score of hormone
sensitive tumors (Figure 2c). No significant differences in
Ebp1 expression were found between Gleason scores (P >
0.05, Mann-U).
Individual expression of Ebp1 does not predict PSA relapse
The prognostic role of Ebp1 with regards to the PSA
relapse following radical prostatectomy was evaluated in
COX univariate regression models on the RP-TMA (Table
2). We observed that the individual expression of Ebp1 in
both normal adjacent and tumor tissues was unable to
predict PSA relapse (P  = 0.170 and P = 0.689, respec-
tively).
Expression of cytokeratins in normal adjacent and tumor tissues Figure 1
Expression of cytokeratins in normal adjacent and tumor tissues. Staining of the basal membrane with the cytokerat-
ins Eβ12 antibody. A) Staining of a normal adjacent tissue with proper basal membrane integrity and continuity. B) Staining of a 
tumor tissue without proper basal membrane integrity and continuity.Cancer Cell International 2008, 8:18 http://www.cancerci.com/content/8/1/18
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Expression of Ebp1 in prostate tissues Figure 2
Expression of Ebp1 in prostate tissues. A) Prostate epithelium stained for Ebp1. Example of the four cytoplasmic staining 
intensities for Ebp1: 0+, 1+, 2+ and 3+. B) Median staining intensity of Ebp1 in normal (n = 39), normal adjacent (n = 53), PIN 
(n = 29), tumor (n = 62) and hormone refractory (n = 36) prostate tissues. Normal tissues come from the N-TMA. Normal 
Adjacent, PIN and tumor tissues come from the RP-TMA. The hormone refractory tissues come from the HR-TMA. Significant 
statistical differences were found Normal vs Normal Adjacent Tissues (P < 0.001, Mann-U), Normal Adjacent vs Tumor Tis-
sues (P < 0.001, Mann-U), PIN vs Tumor (P = 0.003, Mann-U) and Tumor vs Hormonorefractory (P < 0.001, Mann-U). How-
ever, no statistical difference was found between Normal Adjacent vs. PIN (P = 0.464, Mann-U). C) Median staining intensity of 
Ebp1 according to Gleason score. The tissues analyzed are from the tumor cores of the RP-TMA. No significant differences 
were observed (Mann-U).Cancer Cell International 2008, 8:18 http://www.cancerci.com/content/8/1/18
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Expression of Ebp1-associated proteins correlates with 
PSA relapse
Since the expression of Ebp1 correlated with prostate can-
cer progression, we also evaluated whether the expression
of Ebp1 correlated with the nuclear expression of Ebp1
regulated proteins (AR, Cyclin D1 & ErbB3) and the pro-
liferation marker Ki67. The immunohistochemical stain-
ing for these four proteins was completed on the RP-TMA
(Figure 3). Contrary to previously published in vitro data
describing that Ebp1 can inhibit the expression of AR, our
in vivo results illustrated that cytoplasmic Ebp1 positively
correlated with AR nuclear expression in normal adjacent
(Spearman = 0.295, P = 0.032) and tumor tissues (Spear-
man = 0.374, P  = 0.003) (Table 3). We observed that
Ebp1's cytoplasmic expression also correlated strongly
with the nuclear expression of Cyclin D1 and ErbB3 in
both normal adjacent and tumor tissues (Table 3).
Subsequently, we evaluated whether the nuclear expres-
sion of AR, Cyclin D1, ErbB3 and Ki67 could predict PSA
relapse. The level of nuclear expression of AR, Cyclin D1
and ErbB3 in normal adjacent tissue were all associated
with a lower risk of developing PSA relapse in a COX uni-
variate regression model (Table 2). No individual marker
nuclear expression in the tumor tissue was associated with
PSA relapse.
Expression of individual markers in prostate cancer tissue Figure 3
Expression of individual markers in prostate cancer tissue. A) Nuclear staining of androgen receptor. B) Nuclear stain-
ing of Cyclin D1. C) Nuclear and cytoplasmic staining of ErbB3. Inset: Example of a tissue without nuclear ErbB3 staining. D) 
Nuclear staining of Ki67.Cancer Cell International 2008, 8:18 http://www.cancerci.com/content/8/1/18
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Multi-marker combinations are independent predictors of 
PSA relapse
Due to the strong expression correlation between the five
molecular markers, we evaluated whether double and tri-
ple marker combinations could predict PSA relapse in
tumor tissues. Contrary to AR, Cyclin D1, ErbB3 and Ki67
nuclear expression, high Ebp1 expression tended to posi-
tively correlate with a higher risk of PSA relapse (Kaplan-
Meier, data not shown). As such, we studied whether
marker combinations composed of elevated Ebp1 and
low expression of the four other markers were associated
with PSA relapse (e.g. Ebp1+/Cyclin D1-). Of all the vari-
ous combinations analyzed, 8 combinations were associ-
ated with PSA relapse in univariate COX regression
models.
Finally, we investigated the predictive strengths of the
individual maker expression and the various combina-
tions in multivariate models with a base clinical model
composed of: Gleason score (< 7, 7, > 7), pre-operative
PSA levels, surgical margin status and pathological stage
(Table 4). As previously reported in the literature, univar-
iate analyses of the base clinical model showed that the
Gleason score, surgical margin status and P-Stage corre-
lated with PSA relapse [21,22]. In a multivariate analysis,
the Gleason score (HR = 4.21, P = 0.030) and surgical
margin status (HR = 8.06, P < 0.001) were found to be
independent predictors of prostate cancer recurrence. By
adding the molecular markers to the base model, we
found that the two marker combinations in the tumor tis-
sue were identified as independent predictors:
CyclinD1+/ErbB3+ (HR = 0.44, P = 0.034) and Ebp1+/
Cyclin D1- (HR = 4.79, P = 0.003) (Table 4).
Discussion
Prostate cancer continues to represent a serious health
problem for aging men in Western countries. Within the
patients who are treated by radical prostatectomy, it
remains difficult to identify which patients will be at risk
for prostate cancer recurrence. Our goal was to character-
ize Ebp1 expression in prostate cancer tissues obtained
from radical prostatectomy and to evaluate whether Ebp1
could represent a molecular marker capable of identifying
patients at higher risk of disease recurrence or progression.
Our results demonstrate that Ebp1 expression correlated
with the progression from normal, to normal adjacent, to
Table 2: Analyses of overall PSA relapse*.
Univariate analyses†
Normal adjacent expression Tumor expression
Hazard ratio (95% CI); Hazard ratio (95% CI);
p-value p-value
Cut-off (median)‡ Cut-off (median)‡
Ebpl 1.75(0.79–3.89); 1.15(0.58–2.26);
p = 0.170 p = 0.689
Median = 2.00 Median = 2.50
Androgen Receptor 0.48 ((0.24–0.95); 0.51 (0.25–1.02);
p = 0.035 p = 0.056
Median = 61.25 Median = 81.67
Cyclin D1 0.34(0.17–0.69); 0.57(0.29–1.14);
p = 0.002 p = 0.113
Median = 2.50 Median = 14,38
ErbB3 0.42 (0.21–0.85); 1.16(0.59–2.29);
p = 0.016 p = 0.665
Median = 3.75 Median = 5.63
Ki67 1.03 (0.52–2.04); 1.01 (0,52–1,96);
p = 0.936 p = 0.976
Median = 29.50 Median = 127.25
Correlation between PSA relapse and the expression of the five molecular marker expression in normal adjacent and tumor tissues using univariate 
Cox regression analyses. The median value used as the statistical cut-off is also shown.
* Data was categorized according to the median.
†Univariate COX regression with the "ENTER" model
‡Median expression was used as cut-offs for catergorized data.
Bold indicates statistically significant valuesC
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Table 3: Correlation between the expressions of individual markers*. 
Normal adjacent Expression Tumor expression
AR Spearman; 
P-Value
CyclinD1 
Spearman; 
P-Value
Ebp1 
Spearman; 
P-Value
KrbB3 
Spearman; 
P-Value
Ki67 
Spearman; 
P-Value
AR Spearman; 
P-Value
CyclinD1 
Spearman; 
P-Value
ErbB3 
Spearman; 
P-Value
Ebp1 
Spearman; 
P-Value
Ki67 
Spearman; 
P-Value
Normal 
Adjacent
AR ----------
----------
CyclinD1 0.612 ---------
< 0.001 ---------
Kbp1 0.482 0.369 --------
< 0.001 0.007 --------
ErbB3 0.700 0.727 0.425 -------
< 0.001 < 0.001 0.002 -------
Ki67 0.326 0.307 0.362 0 . 1 6 7 ------
0.017 0.025 0.008 0 . 2 3 1 ------
AR 0.504 0.493 0.258 0.482 0 . 0 5 1 -----
< 0.001 < 0.001 0.065 < 0.001 0 . 7 1 8 -----
CyclinD1 0.249 0.370 0.166 0.408 0.340 0,368 ----
0.075 0.007 0.240 0.003 0.014 0.004 ----
ErbB3 0.169 0.030 0.323 0.065 0.354 0.498 0.344 ---
0.232 0.831 0.019 0.646 0.010 < 0.001 0.007 --
Ebp1 0.295 0.317 0.397 0.483 0.190 0.374 0,394 0.348 --
0.032 0.021 0,003 < 0.001 0.172 0.003 0.002 0.006 --
Ki67 0.310 0.083 0.247 0.152 0.436 0.256 0.007 0.285 0.064 --
0.024 0.555 0.074 0.276 0.001 0.046 0.954 0.026 0.622 -
Non-parametric correlations between the expressions of the individual markers.
* The correlation between marker expression was analyzed with continuous, non-categorical values.
Bold indicates statistically significant valuesCancer Cell International 2008, 8:18 http://www.cancerci.com/content/8/1/18
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hormone sensitive prostate cancer and to hormone refrac-
tory prostate cancer. This data is consistent with previ-
ously published results demonstrating an overexpression
of Ebp1 in colorectal cancer [14]. However, contrary to
published  in vitro data using prostate cancer cell lines
[7,11-13,23], no nuclear localized Ebp1 was observed in
the human tissue samples that we tested.
Interestingly, normal adjacent tissue expressed higher lev-
els of Ebp1 than normal tissue from patients without
prostate cancer. We suspect that the difference in expres-
sion of Ebp1 between the two "normal" tissues could be
explained by the tumor's field effect on the surrounding
cells. Normal adjacent tissue was found to contain a
wealth of valuable molecular prognostic information. In
fact, expression of the AR, Cyclin D1 and ErbB3 in normal
adjacent tissue was found to be more informative than the
corresponding tumor tissue in predicting PSA relapse in
univariate models.
Strong positive correlations were also found between the
cytoplasmic expression of Ebp1 and AR, Cyclin D1 and
Erb3. Previous reports have suggested that the anti-prolif-
erative activity of Ebp1 is dependant on its nuclear locali-
zation [24]. We found that cytoplasmic Ebp1 positively
correlated with the nuclear expression Cyclin D1. There
exists two isoforms of Ebp1: the p42 isoform, which
inhibits cellular proliferation, and the p48 isoform, which
promotes proliferation and cell survival [25]. The anti-
body used in this study recognizes the p48 and not the
p42 isoform. Although the expression of two different
Ebp1 isoforms in prostate cancer has not yet been exam-
ined, the expression of p42 and p48 isoforms may explain
Ebp1's regulation of cellular proliferation in prostate can-
cer. In line with this hypothesis, we found that high Ebp1
expression correlated with high nuclear AR expression,
which is inconsistent with in vitro data in LNCaP cells
[12]. Similarly, the inhibition of AR expression and AR-
regulated genes may be dependant on Ebp1's nuclear
Table 4: Univariate and multivariate Cox regression analyses of PSA relapse.
Univariate analyses Multivariate analyses
Base model Base model + CyclinD1+/
ErbB3+(T)
Base model + Ebp1+/
CyclinD1-(T)
Hazard ratio (95% CI); p Hazard ratio (95% CI); p Hazard ratio (95%CI); p Hazard ratio (95%CI); p
Gleason < 7 vs Gleason 7 1.67 0.99 0.96 1.36
(0.78–3.57); (0.45–2.19); (0.43–2.17); (0.58–3.20);
p = 0.186 p = 0.977 p = 0.924 p = 0.484
Gleason < 7 vs Gleason > 7 2.80 4.21 5.75 6.80
(1.15–6.81); (1.65–10.75): (2.14–15.44); (2.40–19.30):
p = 0.023 p = 0.030 p < 0.001 p < 0.001
Pre-Op PSA 1.03 .. .. ..
(0.99–1.07); .. .. ..
p = 0.198 .. .. ..
Surgical Margins 5.97 8.06 9.91 12.06
(2.68–13.3); (3.32–19.55); (3.96–24.81); (4.48–32.49);
p < 0.001 p < 0.001 p < 0.001 p < 0.001
P-Stage 5.15 .. .. ..
(2.49–10.63); .. .. ..
p < 0.001 .. .. ..
Molecular Marker .. .. 0.44 4.79
.. .. (0.20–0.94); (1.73–13.26);
.. .. p = 0.034 p = 0.003
Model P value .. p < 0.001 p < 0.001 p < 0.001
Correlation between PSA relapse and the clinico-pathological parameters using univariate Cox regression analyses. Multi-variate Cox regression 
analysis of the base models and the base model + molecular marker.
* Multi-Variate COX regression was perform under the Forward Wald model
Normal Adjacent Tissues (NA): Tumor Tissues (T)Cancer Cell International 2008, 8:18 http://www.cancerci.com/content/8/1/18
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translocation. Future work should evaluate the expression
of the p42 isoform in prostate cancer.
Furthermore, our results are consistent with results from
our group detailing that ErbB3 does not predict overall
biochemical recurrence except in patients with positive
surgical margins [5]. This study adds to the list of publica-
tions suggesting that nuclear AR expression in tumor tis-
sue is non-informative as a prognostic marker in prostate
cancer [26-29]. However, a high expression of AR in nor-
mal adjacent tissue appears to protect against PSA relapse.
This suggests that the AR in normal adjacent tissues may
play a different role as compared to the AR in tumor tissue
where the high AR expression appears to be implicated in
progression to hormonorefractory disease. Studies have
demonstrated significant differences in the expression
profiles of normal adjacent tissues compared to tumor
cells in prostate [30] and lung cancer [31]. Nonetheless, it
has not been established whether these differences could
be related to disease progression and prognosis. Based on
our findings and those of others, prognostic studies with
molecular markers should not be restricted to tumor tis-
sue [32].
Due to the heterogeneity of prostate tumors, the use of
single markers may only identify a portion of high-risk
tumors. The combination of markers could thus over-
come this limitation. Clearly our findings on multi-
marker combinations as independent predictors of PSA
relapse in prostate needs to be confirmed in a larger study.
Nonetheless these results suggest that combining biomar-
kers could significantly improve our current methods of
risk stratification based on clinical and pathological char-
acteristics. Several studies have shown that including mul-
tiple biological makers with known biological
interactions could significantly improve the predictive
ability of nomograms solely based on clinico-pathologi-
cal parameters [20,33-35]. The next step will be to per-
form these types of analyses on pre-surgery biopsy
samples in order to exploit the predictive strengths of
molecular markers earlier in the decision-making and in
patients undergoing radiotherapy or other non-surgical
therapy.
Conclusion
In this study, we demonstrated that Ebp1 expression
increases with the progression from normal to hormone
sensitive and to hormone refractory prostate cancer.
Although by itself Ebp1 expression did not predict PSA
relapse, two double marker combinations were independ-
ent predictors of PSA relapse in a multivariate model. Val-
idation of these findings in larger cohorts is now essential
for the eventual use of these molecular markers in clinical
practice.
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